SCHEMBL4340119

SCHEMBL4340119

CC(c1ccccc1)C(CC(C(=O)NO)c1nccs1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
CTSA P10619 8/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SLC6A9 P48067 1/20 0.41
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
MMP7 P09237 1/20 0.39
HSPA5 P11021 1/20 0.38
HSPA9 P38646 1/20 0.38
ACP1 P24666 1/20 0.38
NR3C1 P04150 1/20 0.38
MMP8 P22894 1/20 0.38
FFAR2 O15552 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4326210 0.95 CTSA (0.41) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4343417 0.95 CTSA (0.41) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4336819 0.94 FFAR2 (0.47) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4341882 0.94 FFAR2 (0.47) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4322303 0.94 SLC6A9 (0.48) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4320523 0.94 SLC6A9 (0.48) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4325425 0.88 CTSA (0.45) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4329776 0.83 CTSA (0.43) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4330530 0.83 CTSA (0.43) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4341782 0.83 CTSA (0.43) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521563-B2 Hydroxamic acid derivative and medicine containing the same as active ingredient SHIZUOKA COFFEIN CO., LTD. (JP) 2009-04-21 US claimed
US-20070208065-A1 Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient SHIZUOKA COFFEIN CO., LTD. (JP) 2007-09-06 US claimed
EP-1787986-A1 HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT SHIZUOKA COFFEIN CO., LTD. (JP) 2007-05-23 EP claimed
US-7521563-B2 Hydroxamic acid derivative and medicine containing the same as active ingredient SHIZUOKA COFFEIN CO., LTD. (JP) 2009-04-21 US disclosed
US-20070208065-A1 Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient SHIZUOKA COFFEIN CO., LTD. (JP) 2007-09-06 US disclosed
EP-1787986-A1 HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT SHIZUOKA COFFEIN CO., LTD. (JP) 2007-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208065-A1 Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient IL6, IL1A, TNF CYP1A2 1586/4885CYP3A4 2548/4885CYP2D6 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.